Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study

被引：0
|
作者：
Lopez, S. Benavente [1 ]
Mendoza, S. Bolano [1 ]
Gonzalez, A. Parra [1 ]
Fernandez, A. Lara [1 ]
Nevado, A. Herencias [1 ]
Garcia, E. Baca [1 ]
机构：
[1] Hosp Univ Infanta Elena, Psychiat, Madrid, Spain
来源：
EUROPEAN PSYCHIATRY | 2023年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0758
引用
收藏
页码：S489 / S489
页数：1
相关论文
共 50 条
  • [41] PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA: BASELINE INTERIM ANALYSIS OF A NATURALISTIC, 52-WEEK, PROSPECTIVE STUDY
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Peters, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 143 - 144
  • [42] Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia : A Critical Appraisal
    Garcia-Carmona, Juan Antonio
    Pappa, Sofia
    DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 113 - 123
  • [43] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN PSYCHIATRY, 2018, 48 : S107 - S108
  • [44] Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study
    Wallman, Phoebe
    Clark, Ivana
    Taylor, David
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 148 : 131 - 136
  • [45] Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: a one-year, real-world, and retrospective mirror image study in China
    Zhou, Yixiang
    Chen, Binbin
    Huang, Yinghua
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [46] LONG-TERM SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PALIPERIDONE PALMITATE: A ONE-YEAR OPEN-LABEL STUDY IN PATIENTS WITH SCHIZOPHRENIA.
    Coppola, D.
    Liu, Y.
    Gopal, S.
    Remmerie, B.
    Samtani, M.
    Pandina, G.
    Hough, D.
    Nuamah, I.
    Sulaiman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S25 - S25
  • [47] Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice
    Wallman, Phoebe
    Clark, Ivana
    Taylor, David
    JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (09) : 1091 - 1098
  • [48] The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study
    Duarte, C. H. Arteaga
    Fakra, E.
    Van Gils, C.
    Guillon, P.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2019, 45 (06): : 459 - 467
  • [49] Retrospective one-year follow-up study of one-monthly paliperidone palmitate in in-patient unit
    Segura, E.
    Rodriguez, C.
    Asensio, L.
    Nuevo, L.
    Cabanillas, L.
    Gomez, I.
    Beato, L.
    EUROPEAN PSYCHIATRY, 2018, 48 : S194 - S195
  • [50] Retrospective Assessment of Metabolic Syndrome and Cardiovascular Disease Risk Following Monthly and Three-Month Long-Acting Paliperidone Palmitate Treatment in Schizophrenia
    Ispir, S. N.
    Yildiz, E.
    Demirel, H. R.
    Soylemez, H.
    Aydin, M.
    EUROPEAN PSYCHIATRY, 2024, 67 : S214 - S215
12345